News

Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals

ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today…

2 years ago

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in…

2 years ago

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a…

2 years ago

ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

Award to support Phase 2 development of IMSA101, a STING agonist, in solid tumor malignanciesDALLAS, Sept. 20, 2022 (GLOBE NEWSWIRE)…

2 years ago

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of…

2 years ago

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low…

2 years ago

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,…

2 years ago

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for…

2 years ago

Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic

COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed…

2 years ago

Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

San Diego, California, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical…

2 years ago